-
Most Popular
Search Results
240 results for dgse
Europe, America Play Well Together — Thursday’s IP Market Recap
Stocks roared Thursday on a double dose of good news, from the ECB and on the U.S. jobs front. Also, Navistar and Men’s Wearhouse surged…
Novavax Is Oversold, Time To Buy for Future Growth
NVAX stock seems oversold. Focus on low-income countries is likely to deliver revenue and cash flows from covid-19 vaccine sales in 2022.
Developed World Boosters Offer Big Market for Eventual Novavax Vaccine
Novavax’s combination vaccine and its Covid-19 vaccine sales for Q1/2022 in Japan are positive drivers for its revenue in the years ahead.
Big Catalysts Are Just Around the Corner for iBio Stock
Asset prices don’t go up in a straight line, even if the company shows promise. Use the dip in IBIO stock now to get in…
Novavax Is Worth $165 Once Its Covid-19 Vaccine Is Ready
NVAX stock is set to move higher once its Covid-19 vaccine is ready. If its clinical trials succeed, NVAX stock is worth $165 per share,…
Moderna Stock Looks Too Cheap After This Recent Dip
Investors who enjoyed a five-fold return this year are selling now but more upside approaches as Moderna ships vaccines worldwide.
OCGN Stock: The Big COVAXIN News That Ocugen Bulls Should Watch
OCGN stock bulls should pay close attention to the latest news on the COVAXIN vaccine and on speculative social media chatter.
Minerva Neurosciences: NERV Stock Plummets 72% on Schizophrenia Study
Minerva Neurosciences (NERV) is seeing NERV stock nosedive on Friday after announcing results from a recent schizophrenia study.
Is BioNTech a Buy Ahead of Earnings?
Many biotech companies are working on COVID-19 vaccines, but I believe BioNTech stands to be one of the biggest winners in the months ahead.
Why Is Bio-Path (BPTH) Stock Up 89% Today?
Bio-Path stock is up with heavy trading of BPTH shares today alongside positive news from its ongoing clinical trial of BP1002.
ArQule News: ARQL Stock Skyrockets on Blood Cancer Study Results
ArQule (ARQL) stock is skyrocketing more than 30% as the company’s blood cancer drug ARQ 531 has begun showing promise in its early going.
Bristol-Myers’ Near Term Rides on Blood Thinner Study
It’s likely sink-or-swim later this month when results are announced.
Biden Vaccine Rollout Plan Assures Success for Moderna
Moderna stock investors should be glad to know that the government is ordering huge quantities of Covid-19 vaccines from just two companies.
Novavax Stock Is an Underdog You Should Bank On
The development a Covid-19 vaccine is no longer a race to the finish line, but there are still plenty of reasons to buy NVAX stock.
Don’t Count on OTC Lipitor as an Rx for Higher PFE Stock
PFE stock holders are looking forward to cholesterol reducer Lipitor becoming an OTC drug, but Pfizer shareholders may have a long and disappointing wait.
Novavax Looks Like a Good Stock to Trade
For retail traders seeking short-term profits, NVAX stock is looking interesting once again. However, it’s not a good long-term investment.
Novavax Stock Is on the Way with Ramp up in EUA Filings
NVAX has fallen sharply recently, but the time is ripe to buy this stock and take advantage of near-term catalysts like EUA filings.
Ahead of Positive Catalysts, Novavax Stock Is Attractive on Weakness
The patent waiver matter will likely prove to be a “nonissue,” while NVAX stock has many upcoming, positive catalysts.
While Risks Remain, VBI Vaccines Stock Is a Buy at Today’s Prices
Sci-B-Vac’s success will make or break VBIV stock. But the shares’ recent pullback may have created a great buying opportunity.
Zagfen Obesity Drug Trial Results Send ZFGN Soaring
Zagfen shares were flying high on Wednesday following positive results from a Phase III drug trial of its new obesity drug.
Moderna’s Lot Recall Is a Blot Despite Its Recent 2nd Covid-19 Booster Approval
MRNA stock could get hurt from a recent recall in Moderna’s Covid-19 vaccine, despite other recent good news from an EUA approval.
Monkeypox Stocks GOVX, VRAX, SIGA Rocket on Vaccine Shortage Fears
Monkeypox stocks are rallying today amid worries about a shortage of vaccines for the illness in the United States.
Why This Company’s Covid-19 Vaccine Is Just the Beginning
It’s little surprise that some of the companies behind the Covid-19 vaccines have seen their stocks rise. Here’s how investors can benefit.
Does Sorrento Therapeutics Meet the ‘SAD’ Criteria for Vaccines?
If you love to gamble, SRNE stock is the right one for you. Few other companies, if any, have pivoted as hard as Sorrento did…
6 – 10 of 240 results
